▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1494 by analyst upside · 2026-11-13
ZYME
Zymeworks Inc.
Healthcare · Market Cap $2B · P/E 49.9x
ANALYST PRICE TARGET
+61.3%
implied upside to consensus target
Current Price $26.47
Consensus Target $42.69
Bull Target $60.0
Bear Target $32.0
Analysts Covering 13
ANALYST CONSENSUS - BUY
Strong Buy
2
Buy
11
Hold
0
Sell
0
52-Week Low $18.2
52-Week High $31.97
YTD Return -0.6%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) 49.9x
Forward P/E 23.9x
EPS (TTM) $0.53
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $266M
Profit Margin 16.3%
52-WEEK RANGE
52-Week Low $18.2
52-Week High $31.97
Current Price $26.47
Bear Target $32.0
Bull Target $60.0
● Now $26.47 ● Target $42.69
TRADING DATA
Avg Volume 1.1M
YTD Return -0.6%
Analyst Count 13
Consensus Buy
Upside to Target +61.3%
Last Updated 2026-11-13

ANALYST SUMMARY

Zymeworks Inc. (ZYME) is currently trading at $26.47 with a Wall Street consensus price target of $42.69, implying potential upside of 61.3% over the next 12 months. 13 analysts currently cover ZYME, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $60.0, while the most cautious has a target of $32.0.

ZYME operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 0.6% year-to-date and is currently trading near the upper end of its 52-week range of $18.2 – $31.97.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ZYME, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Truist Securities - Reiterated
Buy → Buy 2026-10-28 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-10-07 Building track record
Citigroup - Reiterated
Buy → Buy 2026-09-29 Building track record
Wolfe Research ● Initiated
Outperform 2026-09-17 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-09-03 43% win rate (7 calls)
Citigroup - Reiterated
Buy → Buy 2026-08-26 Building track record
Citizens reit
Market Outperform → Market Outperform 2026-08-26 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-08-26 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
56
out of 100
Coverage depth
20/30
Consensus clarity
9/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →